WO2002092780A3 - Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof - Google Patents
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof Download PDFInfo
- Publication number
- WO2002092780A3 WO2002092780A3 PCT/US2002/015767 US0215767W WO02092780A3 WO 2002092780 A3 WO2002092780 A3 WO 2002092780A3 US 0215767 W US0215767 W US 0215767W WO 02092780 A3 WO02092780 A3 WO 02092780A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- methods
- generating
- antigen binding
- domains
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02747843A EP1421203A4 (en) | 2001-05-17 | 2002-05-17 | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
JP2002589648A JP2004532038A (en) | 2001-05-17 | 2002-05-17 | Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30038101P | 2001-05-17 | 2001-05-17 | |
US60/300,381 | 2001-05-17 | ||
US30090701P | 2001-06-25 | 2001-06-25 | |
US60/300,907 | 2001-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002092780A2 WO2002092780A2 (en) | 2002-11-21 |
WO2002092780A3 true WO2002092780A3 (en) | 2004-03-25 |
Family
ID=26971759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/015767 WO2002092780A2 (en) | 2001-05-17 | 2002-05-17 | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1421203A4 (en) |
JP (1) | JP2004532038A (en) |
WO (1) | WO2002092780A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
PT1691837E (en) | 2003-12-10 | 2012-08-27 | Medarex Inc | Ip-10 antibodies and their uses |
EP2418220B1 (en) | 2003-12-10 | 2017-08-02 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
KR20150041193A (en) | 2004-06-21 | 2015-04-15 | 메다렉스, 엘.엘.시. | Interferon alpha receptor 1 antibodies and their uses |
KR101498834B1 (en) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
PE20080036A1 (en) | 2005-10-21 | 2008-03-06 | Novartis Ag | HUMAN ANTIBODIES TO INTERLEUKIN-13 (IL13) |
JP5512128B2 (en) | 2005-12-08 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | Human monoclonal antibodies against fucosyl GM1 and methods for using anti-fucosyl GM1 |
EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | Human antibodies specific for gastrin materials and methods |
WO2010123874A1 (en) | 2009-04-20 | 2010-10-28 | Oxford Biotherapeutics Ltd. | Antibodies specific to cadherin-17 |
EP2420252A1 (en) | 2006-08-04 | 2012-02-22 | Novartis AG | EPHB3-specific antibody and uses thereof |
JP5244785B2 (en) | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | Monoclonal antibody against stroma-derived factor-1 (SDF-1) |
JP5517619B2 (en) | 2006-08-18 | 2014-06-11 | ノバルティス アーゲー | PRLR-specific antibodies and uses thereof |
MX2009002418A (en) | 2006-09-05 | 2009-04-23 | Medarex Inc | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use. |
PT2486941T (en) | 2006-10-02 | 2017-05-30 | Squibb & Sons Llc | Human antibodies that bind cxcr4 and uses thereof |
DK2068922T3 (en) | 2006-10-19 | 2012-10-08 | Csl Ltd | Anti-IL-13Ralfa1 antibodies and their applications |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
NZ577085A (en) | 2006-11-15 | 2012-06-29 | Medarex Inc | Human monoclonal antibodies to btla and methods of use |
CN103172743B (en) | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | Human Antibodies That Bind Cd22 And Uses Thereof |
KR101519672B1 (en) | 2006-12-07 | 2015-05-29 | 노파르티스 아게 | Antagonist antibodies against ephb3 |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
US9127064B2 (en) | 2006-12-21 | 2015-09-08 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
ES2560532T3 (en) | 2007-11-02 | 2016-02-19 | Novartis Ag | Molecules and methods of modulation of protein 6 related to the low density lipoprotein receptor (LRP6) |
EP2240203B1 (en) | 2008-02-05 | 2014-04-09 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
JP5504587B2 (en) * | 2008-05-27 | 2014-05-28 | 東レ株式会社 | Analysis chip |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
CN102300874B (en) | 2008-12-08 | 2015-08-05 | 卡姆普根有限公司 | TMEM154 polypeptide and polynucleotide and as the purposes of drug targets producing medicine and biological products |
US8420084B2 (en) | 2009-03-05 | 2013-04-16 | Medarex, Inc. | Fully human antibodies specific to CADM1 |
MX2011011338A (en) | 2009-04-27 | 2012-04-19 | Novartis Ag | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit. |
EP3275900A1 (en) | 2009-04-27 | 2018-01-31 | Novartis AG | Compositions and methods for increasing muscle growth |
MY160472A (en) | 2009-07-17 | 2017-03-15 | Bioatla Llc | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
WO2011067711A2 (en) | 2009-12-01 | 2011-06-09 | Compugen Ltd | Novel heparanase splice variant |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
AU2011249783B9 (en) | 2010-05-06 | 2014-11-06 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (LRP6) antibodies |
US9290573B2 (en) | 2010-05-06 | 2016-03-22 | Novartis Ag | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies |
EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
SG10201902596TA (en) | 2010-07-16 | 2019-04-29 | Bioatla Llc | Novel methods of protein evolution |
MX2013001613A (en) | 2010-08-09 | 2013-04-22 | Cyvax Inc | Methods and compositions for preventing a condition. |
DK2606070T3 (en) | 2010-08-20 | 2017-03-27 | Novartis Ag | Antibodies for the epidermal growth factor receptor 3 (HER3) |
EP2616100B1 (en) | 2010-09-17 | 2016-08-31 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
EP2622091B1 (en) | 2010-09-23 | 2019-03-13 | Precision Biologics, Inc. | Colon and pancreas cancer peptidomimetics |
JP2013543384A (en) | 2010-10-05 | 2013-12-05 | ノバルティス アーゲー | Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases |
EP2658971A1 (en) | 2010-12-28 | 2013-11-06 | XOMA Technology Ltd. | Cell surface display using pdz domains |
AU2012241373B2 (en) | 2011-04-15 | 2016-06-09 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
US8569462B2 (en) | 2011-06-03 | 2013-10-29 | Xoma Technology Ltd. | Antibodies specific for TGF-beta and methods for treating thereof |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
WO2013003625A2 (en) | 2011-06-28 | 2013-01-03 | Oxford Biotherapeutics Ltd. | Antibodies |
US9365651B2 (en) | 2011-07-01 | 2016-06-14 | Novartis Ag | Method for treating metabolic disorders by administration of an anti-ActRIIB antibody |
EA201491107A1 (en) | 2011-12-05 | 2014-11-28 | Новартис Аг | ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH FACTOR 3 (HER3), DIRECTED TO DOMAIN II HER3 |
CN108341873B (en) | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | Antibodies to epidermal growth factor receptor 3(HER3) |
BR112014015111A2 (en) | 2011-12-21 | 2017-06-13 | Novartis Ag | p-factor targeting antibody compositions and processes |
MX2014009289A (en) | 2012-02-01 | 2015-09-08 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer. |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
SG11201503567SA (en) | 2012-12-05 | 2015-06-29 | Novartis Ag | Compositions and methods for antibodies targeting epo |
CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
WO2014106176A1 (en) | 2012-12-28 | 2014-07-03 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
WO2015198217A2 (en) | 2013-02-08 | 2015-12-30 | Novartis Ag | Compositions and methods for long-acting antibodies targeting il-17 |
CA2897682C (en) | 2013-02-08 | 2023-03-14 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
UY35620A (en) | 2013-06-21 | 2015-01-30 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
AR096601A1 (en) | 2013-06-21 | 2016-01-20 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
TN2016000057A1 (en) | 2013-08-14 | 2017-07-05 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
CA2935378C (en) | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
SG10201810507WA (en) | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
JP6997619B2 (en) | 2014-06-11 | 2022-01-17 | キャシー・エイ・グリーン | Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity |
WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
DK3177642T3 (en) | 2014-08-07 | 2022-02-21 | Novartis Ag | ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USING IT |
WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
UY36449A (en) | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
UY36687A (en) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | ANTIBODIES AGAINST OX40 AND ITS USES |
EA201792561A1 (en) | 2015-06-05 | 2018-04-30 | Новартис Аг | ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
JP6940479B2 (en) | 2015-08-03 | 2021-09-29 | ノバルティス アーゲー | How to treat FGF21-related disorders |
EA038332B1 (en) | 2015-09-09 | 2021-08-10 | Новартис Аг | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
SI3347377T1 (en) | 2015-09-09 | 2021-06-30 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
US11213586B2 (en) | 2015-11-19 | 2022-01-04 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) |
KR20180089510A (en) | 2015-12-18 | 2018-08-08 | 노파르티스 아게 | Antibodies targeting CD32b and methods of using the same |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
EA201891983A8 (en) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | COMBINED THERAPY BY ANTIBODIES TO CD73 |
JP7184751B2 (en) | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | ANTI-HUMAN VISTA ANTIBODY AND USES THEREOF |
JP7138567B2 (en) | 2016-04-27 | 2022-09-16 | ノバルティス アーゲー | Antibodies against growth differentiation factor 15 and their uses |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
AU2017283787B2 (en) | 2016-06-15 | 2020-09-17 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
JP7027401B2 (en) | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies to TIM3 and its use |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
US11332521B2 (en) | 2016-11-07 | 2022-05-17 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
US11339209B2 (en) | 2016-11-14 | 2022-05-24 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
IL267538B1 (en) | 2016-12-23 | 2024-01-01 | Novartis Ag | Anti-factor xi/xia antibodies for use in preventing, treating, managing or reducing the risk of a thromboembolic disorder or stroke in a subject |
WO2018126060A1 (en) | 2016-12-28 | 2018-07-05 | Invvax, Inc. | Influenza vaccines |
MX2019009498A (en) | 2017-02-08 | 2019-10-02 | Novartis Ag | Fgf21 mimetic antibodies and uses thereof. |
WO2018175460A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Methods for preventing and treating heart disease |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2019003104A1 (en) | 2017-06-28 | 2019-01-03 | Novartis Ag | Methods for preventing and treating urinary incontinence |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
AU2018372135A1 (en) | 2017-11-22 | 2020-05-28 | Novartis Ag | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
US20220089720A1 (en) | 2018-01-12 | 2022-03-24 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
CN111868082A (en) | 2018-02-02 | 2020-10-30 | 博奥泰克尼公司 | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using the same |
CN111886256A (en) | 2018-03-23 | 2020-11-03 | 百时美施贵宝公司 | anti-MICA and/or MICB antibodies and uses thereof |
PE20210313A1 (en) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE |
UY38247A (en) | 2018-05-30 | 2019-12-31 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
WO2020131935A1 (en) | 2018-12-18 | 2020-06-25 | Novartis Ag | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
US20220073619A1 (en) | 2018-12-26 | 2022-03-10 | Imcheck Therapeutics Sas | Btn3a binding proteins and uses thereof |
CA3127236A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
MX2023000547A (en) | 2020-07-16 | 2023-02-13 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules. |
WO2022026446A1 (en) * | 2020-07-27 | 2022-02-03 | Wisconsin Alumni Research Foundation | Methods of making unbiased phage libraries |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2023217743A1 (en) | 2022-05-10 | 2023-11-16 | Imcheck Therapeutics | Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6238884B1 (en) * | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2078518T3 (en) * | 1990-04-05 | 1995-12-16 | Roberto Crea | COMPLETE DISPLACEMENT MUTAGENESIS. |
US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
JP2002537758A (en) * | 1998-09-29 | 2002-11-12 | マキシジェン, インコーポレイテッド | Shuffling of codon-modified genes |
JP2002537836A (en) * | 1999-03-09 | 2002-11-12 | ディベルサ コーポレーション | End selection in directed evolution |
-
2002
- 2002-05-17 EP EP02747843A patent/EP1421203A4/en not_active Withdrawn
- 2002-05-17 WO PCT/US2002/015767 patent/WO2002092780A2/en not_active Application Discontinuation
- 2002-05-17 JP JP2002589648A patent/JP2004532038A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6238884B1 (en) * | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
Non-Patent Citations (1)
Title |
---|
See also references of EP1421203A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9375466B2 (en) | 2007-09-04 | 2016-06-28 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9555087B2 (en) | 2007-09-04 | 2017-01-31 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
Also Published As
Publication number | Publication date |
---|---|
EP1421203A4 (en) | 2005-06-01 |
JP2004532038A (en) | 2004-10-21 |
EP1421203A2 (en) | 2004-05-26 |
WO2002092780A2 (en) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002092780A3 (en) | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof | |
ECSP21023271A (en) | CD20 ANTIBODIES WITH IMPROVED EFFECTOR FUNCTION AND BINDING AFFINITY TO HR RECEIVER | |
WO2006114700A3 (en) | Method of producing human igg antibodies with enhanced effector functions | |
NO20073662L (en) | Antigen-binding molecules that bind EGFR, vectors encoding them, and uses thereof | |
TW200720439A (en) | Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function | |
WO2003078600A3 (en) | Human monoclonal antibodies to influenza m2 protein and methods of making and using same | |
WO2003060080A3 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
TW200510459A (en) | RG1 antibodies and uses thereof | |
BRPI0513135A (en) | polynucleotide libraries, method of producing them, method of identifying a polynucleotide, binding region, suitable medium for use in an electronic device and device | |
CA2068222A1 (en) | Monoclonal antibodies | |
EP1433792A8 (en) | Human receptor proteins, related reagents and methods | |
DK1572745T3 (en) | Antibody anti-human NogoA and its pharmaceutical use | |
WO2004087759A3 (en) | Method and compositions for conversion of antibody activity | |
WO2005065711A3 (en) | Mammalian receptor proteins; related reagents and methods | |
WO2001047953A3 (en) | Antibodies against plasma cells | |
WO2006089002A3 (en) | Method for high throughput screening for antibodies and proteins inducing apoptosis | |
GB0227964D0 (en) | Binding partners for the thyrotropin receptor and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002318140 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002589648 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002747843 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002747843 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002747843 Country of ref document: EP |